ラニビズマブ（遺伝子組換え）［ラニビズマブ後続1］
Ranibizumab (Genetical Recombination) [Ranibizumab Biosimilar 1]


ラニビズマブ［ラニビズマブ後続1］（以下，ラニビズマブ後続1）は，遺伝子組換えヒト化モノクローナル抗体のFab断片であり，マウス抗ヒト血管内皮増殖因子（VEGF）抗体の相補性決定部，ヒトフレームワーク部及びヒトIgG1の定常部からなる．ラニビズマブ後続1は，231個のアミノ酸残基からなるH鎖（γ1鎖）断片及び214個のアミノ酸残基からなるL鎖（κ鎖）から構成されるタンパク質である．

Ranibizumab [Ranibizumab Biosimilar 1] (Ranibizumab Biosimilar 1) is a recombinant humanized monoclonal antibody Fab fragment composed of complementarity-determining regions derived from mouse anti-human vascular endothelial growth factor (VEGF) monoclonal antibody, human framework regions and human IgG1 constant regions. Ranibizumab Biosimilar 1 is a protein composed of an H-chain (γ1-chain) fragment consisting of 231 amino acid residues and an L-chain (κ-chain) consisting of 214 amino acid residues.

[347396-82-1 , ラニビズマブ]